Sanofi Sheds Light On Plans For LixiLan, U300 At ADA

Sanofi released positive data from two Phase III trials showing the next-generation insulin glargine U300 worked as well as Lantus in controlling blood sugar in patients with type 2 diabetes but with night-time benefits. The company also announced plans to initiate a Phase III trial studying a combination of the GLP-1 agonist Lyxumia with Lantus in the first half of 2014.